Cargando…

Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature

Basal cell carcinoma (BCC) is a skin cancer with low local aggressiveness and a low tendency to metastasize. Basosquamous Carcinoma (BSC) represents an aggressive histological subtype of BCC with intermediate features between Squamous Cell Carcinoma (SCC) and BCC. Cemiplimab is currently approved as...

Descripción completa

Detalles Bibliográficos
Autores principales: Proietti, Ilaria, Filippi, Luca, Tolino, Ersilia, Bernardini, Nicoletta, Svara, Francesca, Trovato, Federica, Di Cristofano, Claudio, Petrozza, Vincenzo, Bagni, Oreste, Vizzaccaro, Andrea, Skroza, Nevena, Potenza, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669660/
https://www.ncbi.nlm.nih.gov/pubmed/38001904
http://dx.doi.org/10.3390/biomedicines11112903
_version_ 1785139748700946432
author Proietti, Ilaria
Filippi, Luca
Tolino, Ersilia
Bernardini, Nicoletta
Svara, Francesca
Trovato, Federica
Di Cristofano, Claudio
Petrozza, Vincenzo
Bagni, Oreste
Vizzaccaro, Andrea
Skroza, Nevena
Potenza, Concetta
author_facet Proietti, Ilaria
Filippi, Luca
Tolino, Ersilia
Bernardini, Nicoletta
Svara, Francesca
Trovato, Federica
Di Cristofano, Claudio
Petrozza, Vincenzo
Bagni, Oreste
Vizzaccaro, Andrea
Skroza, Nevena
Potenza, Concetta
author_sort Proietti, Ilaria
collection PubMed
description Basal cell carcinoma (BCC) is a skin cancer with low local aggressiveness and a low tendency to metastasize. Basosquamous Carcinoma (BSC) represents an aggressive histological subtype of BCC with intermediate features between Squamous Cell Carcinoma (SCC) and BCC. Cemiplimab is currently approved as first-line therapy in SCC and second-line therapy in BCC patients who have progressed on or are intolerant of a Hedgehog pathway Inhibitor (HHI). Our study describes the case of a 59-year-old man with BSC who was successfully treated with 5 cycles of Cemiplimab as first-line therapy and Sonidegib as second-line therapy. Currently, the efficacy of Cemiplimab against BSC and other histopathological subtypes of BCC has not been fully elucidated, as has the role of sequential or combination therapy with Cemiplimab and HHI in the management of BSC. The aim of this case report is to highlight the need to outline the use of checkpoint inhibitors in BCCs and focus attention on the synergistic role of Cemiplimab and HHIs in such a controversial entity as BSC.
format Online
Article
Text
id pubmed-10669660
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106696602023-10-26 Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature Proietti, Ilaria Filippi, Luca Tolino, Ersilia Bernardini, Nicoletta Svara, Francesca Trovato, Federica Di Cristofano, Claudio Petrozza, Vincenzo Bagni, Oreste Vizzaccaro, Andrea Skroza, Nevena Potenza, Concetta Biomedicines Case Report Basal cell carcinoma (BCC) is a skin cancer with low local aggressiveness and a low tendency to metastasize. Basosquamous Carcinoma (BSC) represents an aggressive histological subtype of BCC with intermediate features between Squamous Cell Carcinoma (SCC) and BCC. Cemiplimab is currently approved as first-line therapy in SCC and second-line therapy in BCC patients who have progressed on or are intolerant of a Hedgehog pathway Inhibitor (HHI). Our study describes the case of a 59-year-old man with BSC who was successfully treated with 5 cycles of Cemiplimab as first-line therapy and Sonidegib as second-line therapy. Currently, the efficacy of Cemiplimab against BSC and other histopathological subtypes of BCC has not been fully elucidated, as has the role of sequential or combination therapy with Cemiplimab and HHI in the management of BSC. The aim of this case report is to highlight the need to outline the use of checkpoint inhibitors in BCCs and focus attention on the synergistic role of Cemiplimab and HHIs in such a controversial entity as BSC. MDPI 2023-10-26 /pmc/articles/PMC10669660/ /pubmed/38001904 http://dx.doi.org/10.3390/biomedicines11112903 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Proietti, Ilaria
Filippi, Luca
Tolino, Ersilia
Bernardini, Nicoletta
Svara, Francesca
Trovato, Federica
Di Cristofano, Claudio
Petrozza, Vincenzo
Bagni, Oreste
Vizzaccaro, Andrea
Skroza, Nevena
Potenza, Concetta
Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
title Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
title_full Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
title_fullStr Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
title_full_unstemmed Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
title_short Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
title_sort supraorbital basosquamous carcinoma treated with cemiplimab followed by sonidegib: a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669660/
https://www.ncbi.nlm.nih.gov/pubmed/38001904
http://dx.doi.org/10.3390/biomedicines11112903
work_keys_str_mv AT proiettiilaria supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT filippiluca supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT tolinoersilia supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT bernardininicoletta supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT svarafrancesca supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT trovatofederica supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT dicristofanoclaudio supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT petrozzavincenzo supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT bagnioreste supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT vizzaccaroandrea supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT skrozanevena supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature
AT potenzaconcetta supraorbitalbasosquamouscarcinomatreatedwithcemiplimabfollowedbysonidegibacasereportandreviewoftheliterature